Tirzepatide Side Effects: Short- and Long-Term Safety Explained

Short-Term Tirzepatide Side Effects

The most common side effects of tirzepatide involve the digestive system. Clinical studies show gastrointestinal issues affected between 39% and 49% of patients, depending on dose. These symptoms generally appear in the first few weeks, often during dose escalation, and then may improve as the body adjusts. Not all patients experience resolution.

Key GI Side Effects (dose-dependent):

• Nausea: 13–24%
• Diarrhea: 13–21%
• Vomiting: 6–14%
• Reduced appetite: ~10%
• Constipation: 2–9%

Providers may start patients at lower doses and gradually increase, which may help minimize these issues.

‍

Long-Term Safety

Long-term studies, including the SURMOUNT and SURPASS programs, suggest that tirzepatide’s safety profile remains consistent over extended use. Both trials used tirzepatide medication formulations that were later approved as Zepbound®. Most side effects remain gastrointestinal and mild to moderate. Discontinuation rates ranged from 4–7% depending on dose, compared with 2.6% for placebo.

Long-term safety findings include:

• Gallbladder disease occurred more often with tirzepatide than with placebo.
• Increases in pancreatic enzymes were observed, though pancreatitis remained rare (<0.5%).
• Blood pressure decreased by ~4–6 mmHg.
• Total cholesterol and triglycerides improved, while HDL increased.
• More than 90% of participants with prediabetes returned to normal blood sugar after 72 weeks.

‍

Weight Regain After Stopping

Evidence suggests that discontinuing tirzepatide may lead to weight regain within about 12 months after stopping. In extension studies, participants who stopped treatment regained much of the lost weight, while those who continued tirzepatide lost additional weight. The formulation used in the referenced study was later approved as Zepbound®. This pattern is consistent with other GLP-1 medications. Many experts now view ongoing therapy as necessary for sustained benefits, similar to long-term treatment for blood pressure or diabetes.

What studies show after stopping tirzepatide:

• Significant weight regain within 1–2 years.
• Return of blood pressure, cholesterol, and diabetes risk toward baseline.
• Risk of regaining nearly all lost weight if therapy is discontinued.

‍

{{primary-cta}}

‍

Rare but Serious Risks

Most side effects are manageable, but some complications require immediate medical attention.

Serious risks include (appearing on both Zepbound® and Mounjaro® FDA labels):

• Pancreatitis: sudden, severe abdominal pain (may radiate to the back).
• Gallbladder disease: abdominal pain, jaundice, fever, pale stools.
• Severe allergic reactions: difficulty breathing, swelling of the face or throat.
• Hypoglycemia: dizziness, sweating, confusion, rapid heartbeat (especially when combined with insulin or sulfonylureas).
• Thyroid C-cell tumors: observed in animal studies; relevance to humans is uncertain. Tirzepatide should not be used in patients with a history of medullary thyroid carcinoma or MEN2.

‍

Comparison With Other GLP-1 Medications

Tirzepatide differs from other GLP-1 receptor agonists because it also activates GIP receptors. Clinical trials comparing tirzepatide to semaglutide show both drugs cause gastrointestinal side effects, though rates and severity vary. Patients without diabetes generally experienced more side effects than those with type 2 diabetes.

‍

Conclusion

Tirzepatide, found in Mounjaro® and Zepbound® is a well-studied medication with a safety profile that is largely consistent with other GLP-1 receptor agonists. The majority of side effects are mild to moderate, most often involving the digestive system. Rare but serious risks, such as gallbladder disease and pancreatitis, require vigilance. Weight regain is common after stopping treatment, which suggests that long-term use may be necessary for sustained results.

Patients should work closely with their healthcare providers to weigh the risks and benefits of therapy, monitor for potential complications, and decide if tirzepatide is appropriate for their health goals.

Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. We do not claim affiliation with or endorsement by Eli Lilly. Eden coordinates care; licensed providers evaluate and prescribe, and partner pharmacies dispense and label medications.

‍